| Species |
Human |
| Protein Construction |
Expressed with an N-terminal Met.
IL-5 (Ile20-Ser134)
Accession # P05113 |
|
| Purity |
> 95% as analyzed by SDS-PAGE |
| Endotoxin Level |
< 0.2 EU/μg of protein by gel clotting method |
| Biological Activity |
ED50 < 1.0 ng/ml, measured by a cell proliferation assay using TF-1 Cells, corresponding to a specific activity of > 1.0 × 106 units/mg. |
| Expression System |
E. coli |
| Apparent Molecular Weight |
~26.5 kDa, on SDS-PAGE under non-reducing conditions. |
| Formulation |
Lyophilized after extensive dialysis against 25 mM Tris, pH 8.0. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O up to 100 μg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
ED₅₀< 1.0 ng/ml, measured by a cell proliferation assay using TF-1 Cells, corresponding to a specific activity of > 1.0× 10⁶ units/mg.
| Target Background |
Interleukin-5 (IL-5), produced by mast cells, T cells and eosinophils, is responsible for the activities attributed to eosinophil differentiating factor, B cell growth factor II and T cell-replacing factor (TRF). It can increase production and mobilization of eosinophils and CD34+ progenitors from the bone marrow. IL-5 plays an important role in inducing cell-mediated immunity against parasitic infections and certain tumors. IL-5 also promotes differentiation of basophils and primes them for histamine and leukotriene release. |
| Synonyms |
IL5; EDF; BCDFII; TRF |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
